Patents by Inventor Kelvin Hin-Yeong Yong

Kelvin Hin-Yeong Yong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE
    Publication number: 20240228475
    Abstract: Provided herein are processes for the preparation of (S)-2-(2,6-dioxopipelidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl) benzyl)amino)isoindoline-1, 3-dione, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof, which is useful for treating, preventing, and managing various disorders. Also provided are solid forms of various intermediates and products obtained from the processes.
    Type: Application
    Filed: June 17, 2022
    Publication date: July 11, 2024
    Inventors: Ronald CARRASQUILLO-FLORES, Jian CHEN, Patrick CORONA, David DEL VALLE, Robert Francis DUNN, Megan EMMANUEL, Antonio C. FERRETTI, Richard Martin HEID, Amude KASSIM, Mohit KOTHARE, Wei LIU, Geoffrey Eugene PURDUM, Krishnakumar RANGANATHAN, Paula A. TAVARES-GRECO, Kelvin Hin-Yeong YONG, Yong YU, Chengmin ZHANG
  • MK2 inhibitors, synthesis thereof, and intermediates thereto
    Patent number: 11655257
    Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: May 23, 2023
    Assignee: Celgene CAR LLC
    Inventors: Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, Jr., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
  • PROCESS FOR THE PREPARATION OF BROMODOMAIN INHIBITOR
    Publication number: 20230128975
    Abstract: The present invention provides processes of synthesis and purification of a bromodomain inhibitor, Compound 1, which compound includes crystalline forms, amorphous forms, solvates, and hydrates thereof. Embodiments of the disclosure relate to chemical synthesis routes of Compound 1 that provide a scalable method that results in highly pure final product. A further embodiment relates to methods to isolate the most stable polymorph of Compound 1 by crystallization from formic acid and water.
    Type: Application
    Filed: December 14, 2022
    Publication date: April 27, 2023
    Applicant: Celgene Quanticel Research, Inc.
    Inventors: John Fitzgerald Traverse, Kelvin Hin-Yeong Yong, Antonio Christian Ferretti, Hekla Alite, Jonathan Moseley, Antonio Maria Ruda, David Primer, Steven Philp
  • Process for the preparation of bromodomain inhibitor
    Patent number: 11566004
    Abstract: The present invention provides processes of synthesis and purification of a bromodomain inhibitor, Compound 1, which compound includes crystalline forms, amorphous forms, solvates, and hydrates thereof. Embodiments of the disclosure relate to chemical synthesis routes of Compound 1 that provide a scalable method that results in highly pure final product. A further embodiment relates to methods to isolate the most stable polymorph of Compound 1 by crystallization from formic acid and water.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: January 31, 2023
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: John Fitzgerald Traverse, Kelvin Hin-Yeong Yong, Antonio Christian Ferretti, Hekla Alite, Jonathan Moseley, Antonio Maria Ruda, David Primer, Steven Philp
  • PROCESS FOR THE PREPARATION OF BROMODOMAIN INHIBITOR
    Publication number: 20220064121
    Abstract: The present invention provides processes of synthesis and purification of a bromodomain inhibitor, Compound 1, which compound includes crystalline forms, amorphous forms, solvates, and hydrates thereof. Embodiments of the disclosure relate to chemical synthesis routes of Compound 1 that provide a scalable method that results in highly pure final product. A further embodiment relates to methods to isolate the most stable polymorph of Compound 1 by crystallization from formic acid and water.
    Type: Application
    Filed: July 23, 2019
    Publication date: March 3, 2022
    Applicant: Celgene Quanticel Research, Inc.
    Inventors: John Fitzgerald TRAVERSE, Kelvin Hin-Yeong Yong, Antonio Christian Ferretti, Hekla Alite, Jonathan Moseley, Antonio Maria Ruda, David Primer, Steven Philp
  • MK2 INHIBITORS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO
    Publication number: 20210139501
    Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
    Type: Application
    Filed: January 14, 2021
    Publication date: May 13, 2021
    Inventors: Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, JR., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
  • MK2 inhibitors, synthesis thereof, and intermediates thereto
    Patent number: 10894796
    Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: January 19, 2021
    Assignee: Celgene CAR LLC
    Inventors: Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, Jr., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
  • MK2 INHIBITORS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO
    Publication number: 20200102326
    Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
    Type: Application
    Filed: March 15, 2018
    Publication date: April 2, 2020
    Inventors: Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, JR., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
  • Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
    Patent number: 10517873
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: December 31, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Marie Georges Beauchamps, Antonio Christian Ferretti, Robert Hilgraf, Mohit Atul Kothare, Hon-Wah Man, Mark A. Nagy, Kelvin Hin-Yeong Yong, Nanfei Zou
  • SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE
    Publication number: 20190167678
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide.
    Type: Application
    Filed: February 4, 2019
    Publication date: June 6, 2019
    Inventors: Marie Georges Beauchamps, Antonio Christian Ferretti, Robert Hilgraf, Mohit Atul Kothare, Hon-Wah Man, Mark A. Nagy, Kelvin Hin-Yeong Yong, Nanfei Zou
  • Forms and compositions of an ERK inhibitor
    Patent number: 10202364
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of one or both of ERK1 and ERK2.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: February 12, 2019
    Assignee: CELGENE CAR LLC
    Inventors: Antonio Christian Ferretti, Lianfeng Huang, Ying Li, John Traverse, Jean Xu, Kelvin Hin-Yeong Yong, Daozhong Zou
  • FORMS AND COMPOSITIONS OF AN ERK INHIBITOR
    Publication number: 20180362498
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of one or both of ERK1 and ERK2.
    Type: Application
    Filed: June 14, 2018
    Publication date: December 20, 2018
    Inventors: Antonio Christian Ferretti, Lianfeng Huang, Ying Li, John Traverse, Jean Xu, Kelvin Hin-Yeong Yong, Daozhong Zou
  • Forms and compositions of an ERK inhibitor
    Patent number: 10005760
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of one or both of ERK1 and ERK2.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: June 26, 2018
    Assignee: Celgene CAR LLC
    Inventors: Antonio Christian Ferretti, Lianfeng Huang, Ying Li, John Traverse, Jean Xu, Kelvin Hin-Yeong Yong, Daozhong Zou
  • FORMS AND COMPOSITIONS OF AN ERK INHIBITOR
    Publication number: 20170226083
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of one or both of ERK1 and ERK2.
    Type: Application
    Filed: August 12, 2015
    Publication date: August 10, 2017
    Inventors: Antonio Christian Ferretti, Lianfeng Huang, Ying Li, John Traverse, Jean Xu, Kelvin Hin-Yeong Yong, Daozhong Zou
  • SOLID FORMS OF 2-(TERT-BUTYLAMINO)-4-((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYLAMINO)-PYRIMIDINE-5-CARBOXAMIDE, COMPOSITIONS THEREOF AND METHODS OF THEIR USE
    Publication number: 20150210650
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide.
    Type: Application
    Filed: January 29, 2015
    Publication date: July 30, 2015
    Inventors: Antonio Christian Ferretti, Hon-Wah Man, Jale Muslehiddinoglu, Jean Xu, Kelvin Hin-Yeong Yong, Marie Georges Beauchamps, Mohit Atul Kothare, Nanfei Zou, Nathan Andrew Boersen, Ying Li, Ying Ye